Not medical advice. Talk to your provider before using any peptide. Full disclaimer
ACE-031
Also known as: ACVR2B-Fc, soluble ActRIIB-Fc, ACE-031
A single injection produced 3.3% lean mass gain in 29 days. ACE-031 is a soluble ActRIIB decoy receptor, a fusion protein that traps myostatin before it can signal muscle breakdown. Phase 2 confirmed the effect in boys with Duchenne muscular dystrophy, but epistaxis and telangiectasias from off-target BMP-9/10 inhibition ended the clinical program in 2011. Acceleron never restarted it. Community users now work with fixed doses 50 to 400 times below clinical levels, chasing that same lean mass signal while watching their skin for spider veins.
What Is ACE-031?
One injection. 3.3% more lean mass by day 29. That Phase 1 result in 48 postmenopausal women (Attie et al.)[1] remains the single strongest muscle-building response ever recorded from a peptide dose.
ACE-031 (also called soluble ActRIIB-Fc or ACVR2B-Fc) is a recombinant fusion protein. It combines the extracellular domain of activin receptor type IIB with a human IgG1 Fc fragment. The molecule floats through the bloodstream and intercepts myostatin, the primary brake on skeletal muscle growth. Without myostatin signaling, muscle protein synthesis accelerates while protein degradation slows.
The problem is selectivity. ACE-031 also captures activin A, activin B, GDF-11, BMP-9, and BMP-10. Trapping activins likely contributes to its muscle and bone effects. Trapping BMP-9 and BMP-10 destabilizes endothelial cells. The Phase 2 trial in ambulatory boys with Duchenne muscular dystrophy (Campbell et al.)[2] confirmed the muscle gains, showing 5.2% lean mass increase versus 2.6% on placebo. It also confirmed the vascular cost. Epistaxis and telangiectasias appeared at doses of 1.0 to 2.5 mg/kg given biweekly. Acceleron terminated the program in April 2011.
All adverse events resolved after stopping. Community users now dose at 500 to 1500 mcg every two weeks, roughly 50 to 400 times below clinical levels. Whether vascular risk scales linearly with dose is unknown. Forum discussion far outweighs actual use reports; maybe 15 to 30 people have documented personal experience.
How ACE-031 Works
ACE-031 works as a ligand trap. The molecule is a soluble version of the membrane-bound activin receptor type IIB (ActRIIB), fused to a human IgG1 Fc fragment for stability and extended half-life.
Under normal conditions, myostatin (GDF-8) binds to ActRIIB on muscle cell surfaces. That binding recruits the type I receptor ALK4 or ALK5 and triggers phosphorylation of Smad2 and Smad3. These phosphorylated Smads pair with Smad4 and move into the nucleus. There they suppress muscle protein synthesis genes and activate degradation pathways, including MuRF1 and MAFbx/atrogin-1 in the ubiquitin-proteasome system.
ACE-031 intercepts myostatin before it reaches those membrane receptors. No binding means no Smad2/3 phosphorylation, no nuclear translocation, and no brake on muscle growth.
The selectivity problem is straightforward. ActRIIB binds multiple ligands. ACE-031 captures activin A, activin B, and GDF-11 alongside myostatin. Those extra captures probably help with muscle and bone density effects. But ACE-031 also traps BMP-9 and BMP-10. These two ligands signal through ALK1 on endothelial cells and keep blood vessels stable. Removing them causes telangiectasias and epistaxis. The 43% FSH reduction observed in healthy women at 3 mg/kg reflects activin A sequestration; activin A drives pituitary FSH secretion.
ACE-031 Benefits
- ACE-031 benefits center on myostatin inhibition and its downstream effects on lean body mass.
- - Phase 1 data: 3.3% total lean mass gain and 5.1% thigh muscle volume increase from a single 3 mg/kg injection by day 29 (Attie et al., 48 healthy women)[1].
- - Phase 2 DMD trial confirmed it in disease: 5.2% lean mass increase versus 2.6% placebo over 12 weeks (Campbell et al.)[2].
- - Bone mineral density markers improved in the DMD trial, suggesting dual musculoskeletal benefit beyond muscle alone.
- - The 10 to 15 day half-life allows biweekly dosing. One injection every two weeks is the lowest injection burden of any muscle-targeting peptide.
- - Preclinical models showed up to 19% lean mass increase in glucocorticoid-induced muscle loss, pointing to potential in steroid-treated populations.
- - Pharmacokinetics are linear across all tested doses (0.02 to 3 mg/kg), which means dose-response is predictable and scalable.
ACE-031: Science vs Community Consensus
ACE-031 is the strongest proof-of-concept for myostatin inhibition as a muscle-building strategy.
Read the evidence (key study, limitations)
Phase 1 data in healthy women showed statistically significant lean mass gains from a single injection. Phase 2 data in DMD boys confirmed efficacy. But the program was terminated due to vascular adverse events caused by off-target BMP-9/10 inhibition. A 2025 review (PMC11842502) places ACE-031 as a key but failed molecule that informed all subsequent myostatin inhibitor design. A 2025 bioRxiv preprint confirmed efficacy in marmosets, adding primate data to the evidence base.
Attie et al. 2013, "A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers" (PMID 23169607): 48 healthy postmenopausal women, single SC dose 0.02-3 mg/kg, 3.3% lean mass gain at 3 mg/kg by day 29
Only 2 human studies ever completed (Phase 1 + Phase 2 DMD). Phase 2 was terminated early: no full efficacy dataset. No long-term safety data. No dose-finding study in healthy adults for body composition. All community dosing is extrapolated, not validated. The molecule captures BMP-9/10 at every tested dose: it's unclear if there is a dose where muscle effects occur without vascular risk.
ACE-031 generates intense curiosity but very few people have actually used it.
Read the reports (what users report 3, common issues 5)
It's expensive, hard to authenticate, and the vascular side effects are genuinely scary. Community protocols exist but are based on small numbers of self-experimenters working with doses far below clinical trial levels. Most discussion is theoretical: people analyzing the clinical data rather than reporting personal experience.
- Dramatic lean mass potential: the clinical data (3.3% from one injection) is the strongest muscle-building result from any single peptide dose
- Long half-life means infrequent injections: biweekly dosing is convenient
- Unique mechanism that doesn't interfere with hormonal axes (no testosterone suppression)
- Nosebleeds and spider veins are real: the clinical trials confirmed this, and community reports are consistent
- Extremely expensive ($80-200+ per dose depending on source and dose)
- Black-market authenticity is a serious problem: 2025 lab testing confirmed contaminated and mislabeled products
- No established safe dosing protocol: community is guessing based on clinical trial extrapolation
- FSH suppression could affect fertility in women
Science and community agree on mechanism, efficacy direction, and vascular risks. They diverge massively on dose: clinical trials used 35-210 mg per injection; community uses 0.5-1.5 mg. No data bridges this gap: community doses are extrapolated, not validated. The safety profile at community doses is unknown.
ACE-031 Dosage Guide
ACE-031 is a large fusion protein, not a standard peptide. Reconstitution matters more here than with most compounds.
For a 1 mg vial with 1 mL bacteriostatic water: concentration is 1000 mcg/mL. A 500 mcg dose is 50 units on an insulin syringe. A 1000 mcg dose uses the full vial.
For a 5 mg vial with 2 mL bacteriostatic water: concentration is 2500 mcg/mL. A 500 mcg dose is 20 units. A 1000 mcg dose is 40 units. A 1500 mcg dose is 60 units.
Add water slowly along the vial wall. Do not shake. ACE-031 is an 82 kDa protein that can denature with aggressive mixing; swirl gently until clear. If the solution looks cloudy or has particles after reconstitution, do not inject it. Protein aggregation means the compound may be damaged or degraded.
The single biggest concern with ACE-031 is product authenticity. Standard HPLC purity testing tells you the mass is correct, not that the protein is properly folded and glycosylated. SDS-PAGE gel data is the minimum check that the right protein is present. Without it, you're guessing.
Cycling Protocol
The Phase 2 DMD trial used a 12-week treatment period. No established cycling protocol exists for research use outside clinical trials. Extended use is not recommended given the known vascular safety signals. Periodic monitoring for telangiectasias, epistaxis, and gum bleeding should be performed throughout any research protocol.
ACE-031 is a recombinant fusion protein: the immune system can develop anti-drug antibodies (ADAs) with repeated exposure. The related compound ACE-2494 was discontinued specifically because of high ADA rates in Phase 1. Clinical trials used 12-week treatment periods. Cycling off allows ADA titers to decline before re-exposure. Continuous BMP-9/10 suppression raises cumulative vascular risk: breaks allow endothelial recovery.
- Diminishing response over successive cycles: may indicate ADA development neutralizing the drug
- Any vascular symptoms (nosebleeds, new spider veins, gum bleeding): stop immediately, don't wait for end of cycle
- Flu-like symptoms or injection site reactions worsening over time: possible immune sensitization
Or use the universal Peptide Calculator for any peptide.
ACE-031 Protocols by Goal
Expected: Unknown at community doses. Clinical doses produced 3.3-5.2% lean mass gains, but community doses are 50-400x lower. Modest body composition changes if the compound is authentic and bioactive.
Monitor: Baseline CBC + coagulation panel. Weekly skin checks for telangiectasias. FSH/LH if female. Immediate stop protocol for any bleeding event.
How to Inject ACE-031
- 1Step 1
Reconstitute by adding bacteriostatic water slowly along the vial wall. For a 1 mg vial, use 1 mL. For a 5 mg vial, use 2 mL. Swirl gently until the powder dissolves completely. Never shake or vortex.
- 2Step 2
Draw the calculated dose using an insulin syringe (29 to 31 gauge). For 500 mcg from a 1 mg/1 mL vial, draw to the 50 unit mark. For 500 mcg from a 5 mg/2 mL vial, draw to the 20 unit mark. For 1000 mcg from a 5 mg/2 mL vial, draw to the 40 unit mark. For 1500 mcg from a 5 mg/2 mL vial, draw to the 60 unit mark.
- 3Step 3
Inject subcutaneously into the abdomen, upper thigh, or upper arm. Rotate injection sites between doses. With biweekly dosing, you have plenty of time for site recovery.
- 4Inject at a slow, steady pace
ACE-031 is a large protein, and injecting too fast or too shallow can cause local lumps or hardness.
- 5Store reconstituted vials at 2 to 8 degrees Celsius
Use within 14 to 21 days. Do not freeze after reconstitution.
- 6Step 6
No specific timing requirements around meals or sleep were established in clinical trials.
- 7Dose every 14 days
Mark your calendar. The 10 to 15 day half-life supports this interval.
ACE-031 Stacking Protocols
Works With
Theoretical anabolic pairing: myostatin removal + IGF-1 stimulation targets two different growth pathways. Discussed on forums but no human data on the combination.
Growth hormone + myostatin inhibition for maximum muscle growth signaling. Commonly discussed but never studied together in humans.
MGF is a splice variant of IGF-1 released during muscle damage. Combining with ACE-031 theoretically amplifies the growth response. Speculative.
Avoid
Both inhibit myostatin/activin pathways. Stacking two ligand traps risks excessive TGF-beta superfamily suppression with unpredictable vascular and hormonal consequences.
Do not combineACE-031 caused epistaxis and gum bleeding through BMP-9/10 inhibition. Adding blood thinners amplifies bleeding risk substantially.
Do not combineOverlapping TGF-beta/BMP pathway modulation. Co-administration could produce dangerous levels of BMP signaling disruption.
Do not combineEstimated Cost
Pricing updated 2026-04-09
ACE-031 Side Effects
Epistaxis and telangiectasias ended this clinical program. That deserves to lead any safety discussion.
In the Phase 2 DMD trial (Campbell et al.)[2], boys receiving 1.0 to 2.5 mg/kg every two weeks developed nosebleeds and small dilated blood vessels visible on the skin. The mechanism is specific and well understood: ACE-031 sequesters BMP-9 and BMP-10, two ligands that endothelial cells need to maintain vascular integrity. Remove them, and blood vessel walls become fragile. Acceleron Pharma terminated the program in April 2011 because of these signals.
All vascular events resolved completely after stopping the drug. No serious or severe adverse events were reported in either trial. That's the good news. The bad news is that no one knows if there's a dose where muscle effects happen without vascular risk. The molecule captures BMP-9 and BMP-10 at every tested dose.
Published side effects from the two clinical trials include:
Epistaxis (nosebleeds), observed at clinical doses of 1.0 mg/kg and above. This was the primary safety signal.
Telangiectasias (spider veins on skin), same dose range and same mechanism.
Minor gum bleeding, reported in both trials at higher doses.
Erythema at injection sites, mild and transient across all dose levels.
FSH suppression of 43% in healthy postmenopausal women at 3 mg/kg (Phase 1). This reflects activin A sequestration, not a direct hormonal effect. For premenopausal women, this level of FSH disruption could affect ovulation and fertility.
Community reports are limited. Roughly 15 to 30 self-experimenters have shared experiences online. Their doses (500 to 1500 mcg) are 50 to 400 times below clinical levels. Some report nosebleeds even at these low doses. Whether that reflects true pharmacological effect or contaminated product is impossible to determine without product verification.
Long-term safety has never been studied. The clinical program lasted months, not years. Anti-drug antibody formation is a theoretical concern based on the related compound ACE-2494, which was discontinued specifically because of high ADA rates. Anyone with hereditary hemorrhagic telangiectasia, bleeding disorders, or on anticoagulants should not use this compound. Pregnancy is contraindicated given the FSH effects and absence of reproductive safety data.
Stop immediately if you experience any nosebleed, new spider veins, gum bleeding, or unusual bruising. These are the exact signals that terminated a clinical program.
Common Issues & Solutions
No visible results after 8+ weeks: most likely an authenticity problem. ACE-031 is an 82 kDa recombinant protein that requires mammalian cell expression. Standard peptide purity testing (HPLC by mass) can't confirm correct folding, glycosylation, or biological activity. If your source can't provide gel electrophoresis data, the product may be inactive.
Nosebleeds at any dose: stop immediately. This is the exact adverse event that terminated the clinical program. It indicates BMP-9/10 depletion is occurring, and continuing risks progressive vascular destabilization. All trial events resolved on discontinuation.
New spider veins appearing on skin: same mechanism as nosebleeds. Telangiectasias mean endothelial cells are being destabilized. Discontinue and monitor for resolution over 4-8 weeks.
Injection site hardness or lumps: ACE-031 is a large protein. Injecting too quickly or into too-shallow tissue can cause local reactions. Inject slowly, use adequate subcutaneous depth, and rotate sites.
Reconstituted solution looks cloudy or has particles: the protein may have aggregated or denatured. Don't inject cloudy solution. This can happen from excessive agitation, freezing reconstituted solution, or expired product.
Ask AI about this page
Ask AI for a second opinion on ACE-031 dosing and side effects
Contraindications
- Hereditary hemorrhagic telangiectasia (HHT) or any vascular fragility syndrome: ACE-031 inhibits BMP-9/10 signaling critical for vascular integrity
- Active bleeding disorders or concurrent anticoagulant therapy: the compound caused epistaxis and gum bleeding in clinical trials
- Pregnancy and breastfeeding: no reproductive safety data exists, and FSH suppression was observed in healthy women
- Individuals under 18 outside supervised clinical research: pediatric safety data is limited to the halted DMD trial
- Known hypersensitivity to ACE-031 or any Fc-fusion protein
- Pulmonary arterial hypertension: BMP-9/10 signaling disruption may worsen pulmonary vascular disease
Drug Interactions
- Anticoagulants (warfarin, heparin, DOACs): ACE-031 caused epistaxis and gum bleeding through BMP-9/10 inhibition; concurrent use may amplify bleeding risk
- Other myostatin inhibitors (follistatin, bimagrumab): combining multiple myostatin-pathway inhibitors could produce unpredictable effects; no co-administration data exists
- Hormonal contraceptives / fertility treatments: ACE-031 caused a 43% decrease in FSH through activin A sequestration; may interfere with these therapies
- TGF-beta pathway modulators (luspatercept, sotatercept): overlapping ligand pathways; co-administration could result in excessive TGF-beta superfamily inhibition
- Growth Hormone / IGF-1 therapies: potential additive anabolic effects; no interaction data exists
Product Quality
ACE-031 is an ~82 kDa recombinant fusion protein that requires mammalian cell expression, proper folding, and glycosylation to be biologically active. It can't be made by standard solid-phase peptide synthesis. A 2025 study (Reichel, Drug Testing and Analysis) analyzed black-market ACE-031 and found major inconsistencies: some samples contained the right protein, others were degraded or mislabeled. Standard peptide purity testing cannot validate this compound.
- Gel electrophoresis (SDS-PAGE) data is the minimum to confirm the correct molecular weight protein is present
- ACE-031 priced far below $100/mg is a warning sign: mammalian cell expression is expensive
- A vial labeled "99% purity by HPLC" means almost nothing for a recombinant protein: HPLC confirms mass, not folding or activity
- Consider that at community doses (0.5-1.5 mg), you're using such a tiny fraction of the clinically effective dose that product potency issues are amplified
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| CBC with differential | Baseline, then every 4 weeks during use | Not listed |
| Coagulation panel (PT/INR, aPTT) | Baseline and week 4 | Not listed |
| Skin inspection for telangiectasias | Weekly throughout use | Not listed |
| FSH / LH | Baseline and week 8 (especially for women) | Not listed |
| DEXA body composition scan | Baseline and week 12 | Not listed |
Detect any changes in platelet count or coagulation parameters that could indicate vascular effects
ACE-031 caused bleeding events through BMP-9/10 disruption: monitor clotting function
New spider veins are the most visible early warning sign of vascular endothelial destabilization. Check face, chest, arms, and legs in good lighting.
Phase 1 data showed 43% FSH reduction at 3 mg/kg via activin A sequestration. Reproductive hormone monitoring is warranted.
The only objective way to know if the compound is doing anything at community doses. Without pre/post measurement, you're guessing.
ACE-031 Before and After
Based on Phase 1 data, initial increases in lean body mass may begin within the first two weeks following administration. Pharmacokinetic steady state has not yet been reached.
Lean mass gains become measurable by DXA. In the Phase 1 study, peak lean mass increase (3.3%) was observed by day 29 after a single 3 mg/kg dose. Bone mineral density markers may begin to shift.
With repeated dosing (as in the Phase 2 trial), lean mass gains of approximately 5% are possible. Vascular adverse events (telangiectasias, epistaxis) may emerge during this window, particularly at doses of 1 mg/kg or above given biweekly.
What to Expect
Weeks 1-2 (First injection): Phase 1 pharmacokinetic data shows ACE-031 reaches steady circulating levels after the first dose. Myostatin and activin sequestration begins immediately. At community doses (500 to 1500 mcg), expect nothing visible. Most users report no changes, and any "muscle fullness" at this point is likely placebo. No vascular events are expected from a single low dose.
Weeks 3-6 (Building exposure): With biweekly dosing, trough drug levels establish. In clinical trials at much higher doses, lean mass was measurable by DXA at day 29. At community doses, detectable changes are uncertain. Some users claim better workout recovery and slight visual fullness, but separating real effect from training variables and expectation is difficult. This is the window where nosebleeds and telangiectasias could first appear, especially at higher dose ranges.
Weeks 8-12 (Assessment window): The Phase 2 trial showed approximately 5% lean mass gain in DMD boys at clinical doses over this timeframe. At community doses, any effect would be much smaller. Users who report positive results typically describe modest improvements by this point. Those with no results often suspect the product is inactive or mislabeled. If telangiectasias or epistaxis haven't appeared by week 12, vascular tolerance at the current dose is probably acceptable.
Detailed Timeline: Science vs Community
Based on Phase 1 PK data, ACE-031 reaches steady circulating levels. Initial myostatin/activin sequestration begins. No measurable body composition change yet.
Most users report nothing noticeable after one injection at community doses. Some report a vague "fullness" feeling in muscles, likely placebo.
With biweekly dosing, trough levels establish. At clinical doses, lean mass was measurable by DXA at day 29. Community doses are far lower: detectable changes are uncertain.
Some users claim improved workout recovery and slight visible muscle fullness. Hard to separate from placebo and training variables at these doses.
Phase 2 showed ~5% lean mass gain in DMD boys at clinical doses over this timeframe. At community doses, any effect would be much smaller.
Users who report positive results typically describe modest lean mass improvements by this point: nothing dramatic at community doses. Those with no results often suspect product authenticity.
Pharmacokinetics
Source: Half-life of 10-15 days (~240-360 hours) based on Phase 1 single ascending-dose study in healthy postmenopausal women at 3 mg/kg (Attie et al. 2013, PMID 23169607). Linear pharmacokinetics across all tested doses.
Pharmacokinetics: Active Dose Over Time
t½ = 10-15 daysDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Is ACE-031 Legal?
ACE-031 is not approved by the FDA or any regulatory agency worldwide. Acceleron Pharma halted all clinical development in April 2011 after vascular safety signals in the Phase 2 DMD trial. The compound has no IND pathway active and no pharmaceutical manufacturer currently produces it for human use.
ACE-031 is available only as a research chemical. It is sold labeled "for research purposes only" and is not intended for human consumption. WADA prohibits all myostatin inhibitors under category S4.4 (hormone and metabolic modulators); competitive athletes cannot use this compound.
Product authenticity is a serious concern. ACE-031 is an 82 kDa recombinant fusion protein requiring mammalian cell expression systems. A 2025 analysis (Reichel, Drug Testing and Analysis) found major inconsistencies in black-market samples. Standard peptide testing cannot verify biological activity.
This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before using any research compound.
Evidence grade: Phase 2 trial (Peptide Evidence Gap, October 2026)
Who Should Consider ACE-031
- Researchers studying myostatin and TGF-beta superfamily signaling in muscle physiology
- Muscle-wasting disease researchers: ACE-031 demonstrated measurable lean mass gains in DMD patients
- Scientists investigating sarcopenia and age-related muscle loss interventions
- Body composition researchers: Phase 1 showed 3.3% lean mass gain from a single injection
Related Peptides
What Changed for ACE-031
Peptide Schedule Research TeamReviewed Apr 7, 20266 Citations
References
- [1]A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers (Attie et al., Muscle Nerve 2013) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Myostatin inhibitor ACE-031 treatment of ambulatory boys with DMD: Results of a randomized, placebo-controlled clinical trial (Campbell et al., Muscle Nerve 2017) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Myostatin Inhibitors as Therapies for Muscle Wasting Associated with Cancer and Other Disorders (Smith & Lin, Curr Opin Support Palliat Care 2013) (opens in a new tab)PubMed 24157714PubMed
- Myostatin Inhibitors: Panacea or Predicament for Musculoskeletal Disorders? (Suh & Lee, J Bone Metab 2020) (opens in a new tab)PubMed 32911580PubMed
- Challenges and Future Prospects of Targeting Myostatin/Activin A Signaling to Treat Diseases of Muscle Loss (Lee, J Gerontol 2023) (opens in a new tab)PubMed 36738276PubMed
- Therapeutic applications and challenges in myostatin inhibition for enhanced skeletal muscle mass and functions (Mol Cell Biochem 2025) (opens in a new tab)Review
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is ACE-031?
Niche. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: 50–100. Community mentions on Reddit: ~50–100 threads (estimated).
8 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Low search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.